Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
Two widely studied "forever chemicals" — PFOA and PFOS — are linked to a significantly higher risk of estrogen receptor (ER)-negative breast cancer, one of the more aggressive and harder-to-treat forms of the disease. A large prospective study and supporting meta-analysis published in the Journal of Clinical Oncology found hazard ratios as high as 1.93 for PFOS. Researchers say the findings carry major public health weight, especially since ER-negative tumors have few known risk factors.
Two common "forever chemicals" — PFOA and PFOS — are now linked to a meaningfully higher risk of estrogen receptor (ER)-negative breast cancer, one of the most aggressive and difficult-to-treat subtypes. A prospective case-cohort study using data from the Sister Study — a cohort of over 50,000 women — found that women in the highest exposure quartile for both chemicals faced significantly elevated cancer risk. A meta-analysis of seven studies further backed the PFOA association.
Researchers believe PFAS may act through non-hormonal mechanisms, such as epigenetic changes and immune suppression, rather than directly disrupting estrogen pathways. While PFOA and PFOS have largely been phased out of industry, most people still carry measurable levels in their bodies — and scientists are now calling for more focus on the newer replacement PFAS compounds increasingly in use today.
By the Numbers:
Why it matters: ER-negative breast cancers are harder to treat and have fewer known risk factors than hormone-receptor-positive tumors. Identifying PFAS exposure as a potential contributor opens new avenues for prevention — and underscores the urgency of regulating both legacy and next-generation forever chemicals.
